WILLIAM RUSHING: Open Payments
NPI 1952083370 · BROOKHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$636 in 34 payments from 10 companies in 2025. Trend: 2023 $184 · 2024 $579 · 2025 $636
Food & beverage: $636
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $163 |
| E.R. Squibb & Sons, L.L.C. | 10 | $150 |
| Lundbeck LLC | 5 | $106 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Alkermes, Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
Products named: INVEGA SUSTENNA, COBENFY, REXULTI, Auvelity, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, UZEDY.
Industry payments across MS — which companies pay providers there.
